随着抗β-淀粉样蛋白（amyloid-β，Aβ）单克隆抗体逐步进入中国阿尔茨海默病（Alzheimer’s disease，AD）临床诊疗实践，部分患者已完成或接近完成既定治疗周期，临床上开始面临治疗后维持、停药、监测及再启动治疗等问题。然而，目前国内外关于抗Aβ单克隆抗体治疗后的长期管理及类序贯治疗策略尚缺乏统一共识。本文结合现有临床研究证据及上海交通大学医学院附属仁济医院认知中心实践经验，提出抗Aβ单克隆抗体的类序贯治疗经验性管理方案。方案以淀粉样蛋白PET定量Centiloid值为核心客观依据，建议结合临床清除状态及既往淀粉样蛋白清除速率进行分层管理。停药后，建议结合外周血p-tau217蛋白和淀粉样蛋白PET进行动态监测，并以Centiloid值再次升高至＞24.1 CL作为重新启动抗Aβ单克隆抗体治疗的重要参考。本文方案主要供临床参考，未来仍需真实世界研究和长期随访数据进一步验证与优化。

With the increasing clinical use of anti-amyloid-β (Aβ) monoclonal antibodies in Alzheimer's disease (AD) in China, some patients have completed or are approaching the predefined treatment period, leading to emerging clinical questions regarding post-treatment maintenance, discontinuation, monitoring, and retreatment. However, no consensus has yet been established on long-term management or sequential-like treatment strategies after anti-Aβ monoclonal antibody therapy. Based on current clinical evidence and the practical experience of the Cognitive Center of Renji Hospital, Shanghai Jiao Tong University School of Medicine, this article proposes an experience-based protocol for sequential-like management of anti-Aβ monoclonal antibody therapy. The protocol uses amyloid PET-derived Centiloid values as the core objective reference and recommends stratified management according to clinical clearance status and prior amyloid clearance rate. After treatment discontinuation, dynamic monitoring with plasma p-tau217 protein and amyloid PET is recommended, and an increase in the Centiloid value to >24.1 CL may serve as an important reference for restarting anti-Aβ monoclonal antibody therapy. This protocol is intended to provide a clinical reference and requires further validation and optimization through real-world studies and long-term follow-up.